HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient.

AuthorsHiromichi Shirasu, Akira Ono, Toshiaki Takahashi
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 12 Issue 4 Pg. e33-e34 (04 2017) ISSN: 1556-1380 [Electronic] United States
PMID28343544 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Nivolumab
Topics
  • Adenocarcinoma (drug therapy, pathology)
  • Adenocarcinoma of Lung
  • Aged
  • Antibodies, Monoclonal (administration & dosage, pharmacology, therapeutic use)
  • Humans
  • Lung Neoplasms (drug therapy, pathology)
  • Male
  • Nivolumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: